Abstract
Regulatory T (Treg) cells are a kind of immunosuppression cells, which have been used to treat autoimmune diseases and induce allograft tolerance in clinical trials. While Treg cells based therapy is a promising treatment for kidney diseases and an emerging concept for tolerance induction in renal transplantation, a better understanding of the functions and biology of Treg cells is needed to be able to optimally exploit them. Epigenetics regulation, which refers to potentially heritable alterations in gene expression without underlying changes of the nucleotide sequence, plays an important role in Treg cells induction and maintenance. The expression of Foxp3, the key factor of Treg cells, is regulated by DNA methylation, histone modification and post-transcriptionally modification. Herein, we review the current understanding of Treg cells in kidney diseases and transplantation, and discuss the epigenetic regulation of Treg cells.
Keywords: Epigenetic regulation, Regulatory T cells, Kidney, Transplantation, Treg cells, DNA.
Current Gene Therapy
Title:Epigenetic Regulation of Regulatory T Cells in Kidney Disease and Transplantation
Volume: 17 Issue: 6
Author(s): Yufeng Liu *, Bo Peng, Shengdi Wu and Nuo Xu
Affiliation:
- Department of Nursing, General Surgery, Zhongshan Hospital, Fudan University, Shanghai 200032,China
Keywords: Epigenetic regulation, Regulatory T cells, Kidney, Transplantation, Treg cells, DNA.
Abstract: Regulatory T (Treg) cells are a kind of immunosuppression cells, which have been used to treat autoimmune diseases and induce allograft tolerance in clinical trials. While Treg cells based therapy is a promising treatment for kidney diseases and an emerging concept for tolerance induction in renal transplantation, a better understanding of the functions and biology of Treg cells is needed to be able to optimally exploit them. Epigenetics regulation, which refers to potentially heritable alterations in gene expression without underlying changes of the nucleotide sequence, plays an important role in Treg cells induction and maintenance. The expression of Foxp3, the key factor of Treg cells, is regulated by DNA methylation, histone modification and post-transcriptionally modification. Herein, we review the current understanding of Treg cells in kidney diseases and transplantation, and discuss the epigenetic regulation of Treg cells.
Export Options
About this article
Cite this article as:
Liu Yufeng *, Peng Bo, Wu Shengdi and Xu Nuo, Epigenetic Regulation of Regulatory T Cells in Kidney Disease and Transplantation, Current Gene Therapy 2017; 17 (6) . https://dx.doi.org/10.2174/1566523218666180214093813
DOI https://dx.doi.org/10.2174/1566523218666180214093813 |
Print ISSN 1566-5232 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5631 |
Call for Papers in Thematic Issues
Programmed Cell Death Genes in Oncology: Pioneering Therapeutic and Diagnostic Frontiers (BMS-CGT-2024-HT-45)
Programmed Cell Death (PCD) is recognized as a pivotal biological mechanism with far-reaching effects in the realm of cancer therapy. This complex process encompasses a variety of cell death modalities, including apoptosis, autophagic cell death, pyroptosis, and ferroptosis, each of which contributes to the intricate landscape of cancer development and ...read more
Related Journals
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Infantile Epileptic Encephalopathy with Hypsarrhythmia (Infantile Spasms/West Syndrome) and Immunity
Central Nervous System Agents in Medicinal Chemistry Celastrol and Terpenes as Anti-Infective Agents
Anti-Infective Agents in Medicinal Chemistry Lymphoid-Specific Tyrosine Phosphatase (Lyp): A Potential Drug Target For Treatment of Autoimmune Diseases
Current Drug Targets CD24 in Experimental Autoimmune Encephalomyelitis and Multiple Sclerosis: Targeting Redundancy for Immunotherapy?
Current Immunology Reviews (Discontinued) Mucosal Healing in Ulcerative Colitis: Where do we Stand?
Current Drug Targets Natural Killer T Cells as Targets for Therapeutic Intervention in Autoimmune Diseases
Current Pharmaceutical Design CCR1 Chemokine Receptor Antagonist
Current Pharmaceutical Design Role of Leptin in the Immune System
Current Immunology Reviews (Discontinued) The Unique Inhibitory IgG Receptor--FcγRIIb
Protein & Peptide Letters Editorial (Thematic Issues: Heads Or Tails: Betting On CD6 As a Resurged Target For Autoimmune Diseases and Sepsis)
Current Drug Targets MICA Molecules in Disease and Transplantation, a Double-Edged Sword?
Current Immunology Reviews (Discontinued) Biological Therapies of Autoimmune Diseases
Current Drug Targets - Inflammation & Allergy Effects of Secondhand Smoke on Thyroid Function
Inflammation & Allergy - Drug Targets (Discontinued) Novel Superactive Leptin Antagonists and their Potential Therapeutic Applications
Current Pharmaceutical Design Synthetic Peptides: The Future of Patient Management in Systemic Rheumatic Diseases?
Current Medicinal Chemistry Cosignaling Complexity Gets More Convoluted: The Emerging Importance of the B7-Like Butyrophilin Family of Immune Regulators
Current Immunology Reviews (Discontinued) Manipulating Thymic Apoptosis for Future Therapy of Autoimmune Diseases
Current Pharmaceutical Design T-Lymphocytes: A Target for Stimulatory and Inhibitory Effects of Zinc Ions
Endocrine, Metabolic & Immune Disorders - Drug Targets Recent Advances in the Development of Novel Therapeutics Targeting Dendritic Cells
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery (Discontinued) Systemic Sclerosis-Related Interstitial Lung Disease
Current Respiratory Medicine Reviews